Hepatitis Monthly

Published by: Kowsar

Opioid Drugs in Patients With Liver Disease: A Systematic Review

Hassan Soleimanpour 1 , Saeid Safari 2 , Kavous Shahsavari Nia 3 , Sarvin Sanaie 4 and Seyed Moayed Alavian 5 , 6 , *
Authors Information
1 Road Traffic Injury Research Center, Tabriz University of Medical Sciences, Tabriz, IR Iran
2 Pain Research Center, Iran University of Medical Sciences, Tehran, IR Iran
3 Emergency Medicine Research Team, Tabriz University of Medical Sciences, Tabriz, IR Iran
4 Tuberculosis and Lung Research Center, Tabriz University of Medical Sciences, Tabriz, IR Iran
5 Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
6 Tehran Hepatitis Center, Tehran, IR Iran
Article information
  • Hepatitis Monthly: April 01, 2016, 16 (4); e32636
  • Published Online: March 6, 2016
  • Article Type: Review Article
  • Received: August 21, 2015
  • Revised: December 27, 2015
  • Accepted: December 27, 2015
  • DOI: 10.5812/hepatmon.32636

To Cite: Soleimanpour H, Safari S, Shahsavari Nia K, Sanaie S, Alavian S M. et al. Opioid Drugs in Patients With Liver Disease: A Systematic Review, Hepat Mon. 2016 ;16(4):e32636. doi: 10.5812/hepatmon.32636.

Abstract
Copyright © 2016, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Evidence Acquisition
3. Results
4. Conclusions
Acknowledgements
Footnotes
References
  • 1. Kamath PS, Kim WR, Advanced Liver Disease Study . The model for end-stage liver disease (MELD). Hepatology. 2007; 45(3): 797-805[DOI][PubMed]
  • 2. Soleimanpour H, Safari S, Rahmani F, Jafari Rouhi A, Alavian SM. Intravenous Hypnotic Regimens in Patients With Liver Disease; A Review Article. Anesthesiology and Pain Medicine. 2015; 5(1)[DOI]
  • 3. Murray JF, Dawson AM, Sherlock S. Circulatory changes in chronic liver disease. Am J Med. 1958; 24(3): 358-67[DOI]
  • 4. Harrison principle of internal medicine. 18th 2012;
  • 5. Hoofnagle J. Fulminant hepatic failure: Summary of a workshop*1. Hepatology. 1995; 21(1): 240-52[DOI]
  • 6. Soleimanpour H, Safari S, Rahmani F, Ameli H, Alavian SM. The Role of Inhalational Anesthetic Drugs in Patients with Hepatic Dysfunction: A Review Article. Anesthesiology and Pain Medicine. 2015; 5(1)[DOI]
  • 7. Parker BM, Bhatia S, Younossi Z, Henderson JM, Tetzlaff JE. Autonomic dysfunction in end-stage liver disease manifested as defecation syncope: impact of orthotopic liver transplantation. Liver Transpl Surg. 1999; 5(6): 497-501[PubMed]
  • 8. De Wolf AM. 6/2/06 Perioperative assessment of the cardiovascular system in ESLD and transplantation. Int Anesthesiol Clin. 2006; 44(4): 59-78
  • 9. Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med. 2011; 365(2): 147-56[DOI][PubMed]
  • 10. Njoku DB. Drug-induced hepatotoxicity: metabolic, genetic and immunological basis. Int J Mol Sci. 2014; 15(4): 6990-7003
  • 11. Lewis JH, Stine JG. Review article: prescribing medications in patients with cirrhosis–a practical guide. AP and t. 2013; 37(12): 1132-56
  • 12. Zamora Nava LE, Valadez JA, Chávez-Tapia NC, Torre A. Acute-on-chronic liver failure: a review. Ther Clin Risk Manag. 2014; 10
  • 13. Tegeder I, Lotsch J, Geisslinger G. Pharmacokinetics of opioids in liver disease. Clin Pharmacokinet. 1999; 37(1): 17-40[DOI][PubMed]
  • 14. Swetz KM, Carey EC, Rho RH, Mauck WD, Whitford KJ, Moynihan TJ, et al. Safe use of opioids to manage pain in patients with cirrhosis. Mayo Clin Proc. 2010; 85(10): 959[DOI][PubMed]
  • 15. Golzari SEJ, Soleimanpour H, Rahmani F, Mehr NZ, Safari S, Heshmat Y, et al. Therapeutic approaches for renal colic in the emergency department: a review article. Anesthesiology and pain medicine. 2014; 4(1)
  • 16. Chandok N, Watt KD. Pain management in the cirrhotic patient: the clinical challenge. Mayo Clin Proc. 2010; 85(5): 451-8[DOI][PubMed]
  • 17. Rhee C, Broadbent AM. Palliation and liver failure: palliative medications dosage guidelines. J Palliat Med. 2007; 10(3): 677-85[DOI][PubMed]
  • 18. Ferslew BC, Johnston CK, Tsakalozou E, Bridges AS, Paine MF, Jia W, et al. Altered morphine glucuronide and bile acid disposition in patients with nonalcoholic steatohepatitis. Clinical Pharmacology & Therapeutics. 2015; 97(4): 419-27[DOI]
  • 19. Dzierlenga AL, Clarke JD, Hargraves TL, Ainslie GR, Vanderah TW, Paine MF, et al. Mechanistic Basis of Altered Morphine Disposition in Nonalcoholic Steatohepatitis. Journal of Pharmacology and Experimental Therapeutics. 2015; 352(3): 462-70[DOI]
  • 20. Chen JP, Jawan B, Chen CL, Wang CH, Cheng KW, Wang CC, et al. Comparison of Postoperative Morphine Requirements in Healthy Living Liver Donors, Patients With Hepatocellular Carcinoma Undergoing Partial Hepatectomy, and Liver Transplant Recipients. Transplantation Proceedings. 2010; 42(3): 701-2[DOI]
  • 21. Shinagawa J, Hashimoto Y, Ohmae Y. [A case of hepatic encephalopathy induced by adverse effect of morphine sulfate]. Gan To Kagaku Ryoho. 2008; 35(6): 1025-7[PubMed]
  • 22. Razaq M, Balicas M, Mankan N. Use of hydromorphone (Dilaudid) and morphine for patients with hepatic and renal impairment. Am J Ther. 2007; 14(4): 414-6[DOI][PubMed]
  • 23. Kim TW, Harbott M. The use of caudal morphine for pediatric liver transplantation. Anesth Analg. 2004; 99(2): 373-4[DOI][PubMed]
  • 24. Kotb HI, el-Kabsh MY, Emara SE, Fouad EA. Pharmacokinetics of controlled release morphine (MST) in patients with liver cirrhosis. Br J Anaesth. 1997; 79(6): 804-6[PubMed]
  • 25. Hasselstrom J, Eriksson S, Persson A, Rane A, Svensson JO, Sawe J. The metabolism and bioavailability of morphine in patients with severe liver cirrhosis. Br J Clin Pharmacol. 1990; 29(3): 289-97[PubMed]
  • 26. Crotty B, Watson KJ, Desmond PV, Mashford ML, Wood LJ, Colman J, et al. Hepatic extraction of morphine is impaired in cirrhosis. Eur J Clin Pharmacol. 1989; 36(5): 501-6[PubMed]
  • 27. Mazoit JX, Sandouk P, Zetlaoui P, Scherrmann JM. Pharmacokinetics of unchanged morphine in normal and cirrhotic subjects. Anesth Analg. 1987; 66(4): 293-8[PubMed]
  • 28. Patwardhan RV, Johnson RF, Hoyumpa AJ, Sheehan JJ, Desmond PV, Wilkinson GR, et al. Normal metabolism of morphine in cirrhosis. Gastroenterology. 1981; 81(6): 1006-11[PubMed]
  • 29. Imani F, Motavaf M, Safari S, Alavian SM. The therapeutic use of analgesics in patients with liver cirrhosis: a literature review and evidence-based recommendations. Hepat Mon. 2014; 14(10)[DOI][PubMed]
  • 30. Mort JR, Shiyanbola OO, Ndehi LN, Xu Y, Stacy. J. N. . Opioid-paracetamol prescription patterns and liver dysfunction: a retrospective cohort study in a population served by a US health benefits organization. Drug Saf. 2011; 34(11): 1079-88[DOI]
  • 31. Bosilkovska M, Walder B, Besson M, Daali Y, Desmeules J. Analgesics in patients with hepatic impairment: pharmacology and clinical implications. Drugs. 2012; 72(12): 1645-69
  • 32. Katzung BG, Antony J. Basic and Clinical Pharmacology. 2010;
  • 33. Tegeder I, Geisslinger G, Lotsch J. [Therapy with opioids in liver or renal failure]. Schmerz. 1999; 13(3): 183-95[DOI][PubMed]
  • 34. Grewal RP, Yu KT, Barton NW, Parker RI, Bisceglie AM. Liver biopsies in patients with lysosomal storage disease: experience with effective sedation. Indian J Pediatr. 1997; 64(6): 887-91[PubMed]
  • 35. Danziger LH, Martin SJ, Blum RA. Central nervous system toxicity associated with meperidine use in hepatic disease. Pharmacotherapy. 1994; 14(2): 235-8[PubMed]
  • 36. Pond SM, Tong T, Benowitz NL, Jacob P, Rigod J. Presystemic metabolism of meperidine to normeperidine in normal and cirrhotic subjects. Clin Pharmacol Ther. 1981; 30(2): 183-8[PubMed]
  • 37. Dwyer JP, Jayasekera C, Nicoll A. Analgesia for the cirrhotic patient: a literature review and recommendations. J Gastroenterol Hepatol. 2014; 29(7): 1356-60[DOI][PubMed]
  • 38. Tintinalli JE, Krome RL, Ruiz E. Emergency Medicine: A Comprehensive Study Guide. Adv Emerg Nurs J. 2010; 14(3): 74
  • 39. Murphy EJ. Acute pain management pharmacology for the patient with concurrent renal or hepatic disease. Anaesth Intensive Care. 2005; 33(3): 311-22[PubMed]
  • 40. Saxon AJ, Ling W, Hillhouse M, Thomas C, Hasson A, Ang A, et al. Buprenorphine/Naloxone and methadone effects on laboratory indices of liver health: A randomized trial. Drug Alcohol Depend. 2013; 128(1-2): 71-6[DOI]
  • 41. hepatitis. 2011;
  • 42. Frank G, Wall LR, Rao SP, Rama B. Toxicologic Emergencies. 2012;
  • 43. Loughrey MB, Loughrey CM, Johnston S, O’Rourke D. Fatal hepatic failure following accidental tramadol overdose. Forensic Sci Int. 2003; 134(2-3): 232-3[DOI]
  • 44. Koth HI, Fouad IA, Fares KM, Mostafa MG, Abd El-Rahman AM. Pharmacokinetics of oral tramadol in patients with liver cancer. J Opioid Manag. 2008; 4(2): 99-104[PubMed]
  • 45. Zuin M, Giorgini A, Selmi C, Battezzati PM, Cocchi CA, Crosignani A, et al. Acute liver and renal failure during treatment with buprenorphine at therapeutic dose. Digestive and Liver Disease. 2008; 41(7)[DOI]
  • 46. Taura P, Fuster J, Blasi A, Martinez-Ocon J, Anglada T, Beltran J, et al. Postoperative pain relief after hepatic resection in cirrhotic patients: the efficacy of a single small dose of ketamine plus morphine epidurally. Anesth Analg. 2003; 96(2): 475-80[PubMed]
  • 47. Donaher PA, Welsh C. Managing opioid addiction with buprenorphine. Am Fam Physician. 2006; 73(9)
  • 48. Soyka M, Backmund M, Schmidt P, Apelt S. Buprenorphine-naloxone treatment in opioid dependence and risk of liver enzyme elevation: Results from a 12-month observational study. Am J Addict . 2014; 23(6): 563-9[DOI]
  • 49. Eiden C, Ripault MP, Larrey D, Faillie JL, Pinzani V, Pageaux GP, et al. Acute Hepatitis and Renal Failure Related to Intranasal Buprenorphine Misuse: Case Report and Analysis of Cases Reported to the French Network for Drug Monitoring. Ann Pharmacother. 2013; 47(12): 1721-6[DOI]
  • 50. Ciccozzi MDA, Angeletti M, Baldascino MDG, Petrucci MDE, Bonetti MDC, De Santis MDS, et al. High dose of buprenorphine in terminally ill patient with liver failure: Efficacy and tolerability. J Opioid Manag. 2012; 8(4): 253-9[DOI]
  • 51. Reddy L, Krajnik M, Zylicz Z. Transdermal buprenorphine may be effective in the treatment of pruritus in primary biliary cirrhosis. J Pain Symptom Manage. 2007; 34(5): 455-6[DOI][PubMed]
  • 52. Bruce RD, Altice FL. Case series on the safe use of buprenorphine/naloxone in individuals with acute hepatitis C infection and abnormal hepatic liver transaminases. Am J Drug Alcohol Abuse. 2007; 33(6): 869-74[DOI][PubMed]
  • 53. Deybach JC, Blanlœil Y. Buprenorphine (Temgesic) can be used in hepatic porphyria. Ann Fr Anesth Reanim. 1989; 8(5): 525[DOI]
  • 54. Juby LD, Wong VS, Losowsky MS. Buprenorphine and hepatic pruritus. Br J Clin Pract. 1994; 48(6): 331[PubMed]
  • 55. Pond SM, Tong T, Benowitz NL, Jacob P. Enhanced bioavailability of pethidine and pentazocine in patients with cirrhosis of the liver. Aust N Z J Med. 1980; 10(5): 515-9[PubMed]
  • 56. Bergeron L, Guy C, Ratrema M, Beyens MN, Mounier G, Ollagnier M. [Dextropropoxyphene hepatotoxicity: four cases and literature review]. Therapie. 2002; 57(5): 464-72[PubMed]
  • 57. Rosenberg WMC, Ryley NG, Trowell JM, Mc Gee JO'D, Chapman RW. Dextropropoxyphene induced hepatotoxicity: a report of nine cases. Journal of Hepatology. 1993; 19(3): 470-4[DOI]
  • 58. Ko JS, Shin YH, Gwak MS, Jang CH, Kim GS, Lee SK. The Relationship between Postoperative Intravenous Patient-Controlled Fentanyl Analgesic Requirements and Severity of Liver Disease. Transplantation Proceedings. 2012; 44(2): 445-7[DOI]
  • 59. Haberer JP, Schoeffler P, Couderc E, Duvaldestin P. Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis. Br J Anaesth. 1982; 54(12): 1267-70[PubMed]
  • 60. Jin S.J, Jung J.Y, Noh M.H, Lee S.H, Lee E.K, Choi B.M, et al. The Population Pharmacokinetics of Fentanyl in Patients Undergoing Living Donor Liver Transplantation. Clin Pharmacol Ther. 2011; 90(3): 423-31
  • 61. Pouraghaei M, Moharamzadeh P, Soleimanpour H, Rahmani F, Safari S, Mahmoodpoor A, et al. Comparison Between the Effects of Alfentanil, Fentanyl and Sufentanil on Hemodynamic Status During Rapid Sequence Intubation in the Emergency Department. Anesth Pain Med. 2014; 3(3)[DOI]
  • 62. Servin FS. Remifentanil: an update. Curr Opin Anaesthesiol. 2003; 16(4): 367-72[DOI]
  • 63. Hagiwara C, Mizutani K, Fukukita K, Asada A. [Use of remifentanil in a patient with renal failure and liver dysfunction undergoing hepatectomy]. Masui. 2009; 58(5): 623-5
  • 64. McCammon RL, Viegas OJ, Stoelting RK, Dryden GE. Naloxone Reversal of Choledochoduodenal Sphincter Spasm Associated with Narcotic Administration. Anesthesiology. 1978; 48(6): 437[DOI]
  • 65. Dershwitz M, Rosow CE. The pharmacokinetics and pharmacodynamics of remifentanil in volunteers with severe hepatic or renal dysfunction. JCA. 1996; 8(3)-90[DOI]
  • 66. Dumont L, Picard V, Marti RA, Tassonyi E. Use of remifentanil in a patient with chronic hepatic failure. Br J Anaesth. 1998; 81(2): 265-7[PubMed]
  • 67. Wilhelm W, Kreuer S. The place for short-acting opioids: special emphasis on remifentanil. Critical Care. 2008; 12
  • 68. Chauvin M, Ferrier C, Haberer JP, Spielvogel C, Lebrault C, Levron JC, et al. Sufentanil pharmacokinetics in patients with cirrhosis. Anesth Analg. 1989; 68(1): 1-4[PubMed]
  • 69. Baririan N, Van Obbergh L, Desager JP, Verbeeck RK, Wallemacq P, Starkel P, et al. Alfentanil-induced miosis as a surrogate measure of alfentanil pharmacokinetics in patients with mild and moderate liver cirrhosis. Clin Pharmacokinet. 2007; 46(3): 261-70[DOI][PubMed]
  • 70. Davis PJ, Stiller RL, Cook DR, Brandom BW, Davis JE, Scierka AM. Effects of cholestatic hepatic disease and chronic renal failure on alfentanil pharmacokinetics in children. Anesth Analg. 1989; 68(5): 579-83[PubMed]
  • 71. Fairbank E. Opioid Use in LiverFailure.
  • 72. Soleimanpour H, Rahmani F, Safari S, Golzari SE. Hypothermia after cardiac arrest as a novel approach to increase survival in cardiopulmonary cerebral resuscitation: a review. Iran Red Crescent Med J. 2014; 16(7)[DOI][PubMed]
  • 73. Soleimanpour H, Hassanzadeh K, Vaezi H, Ej Golzari S, Esfanjani R, Soleimanpour M. Effectiveness of intravenous lidocaine versus intravenous morphine for patients with renal colic in the emergency department. BMC Urology. 2012; 12(1): 13[DOI]
  • 74. Mahmoodpoor A, Soleimanpour H, Nia KS, Panahi JR, Afhami M, Golzari SE, et al. Sensitivity of palm print, modified mallampati score and 3-3-2 rule in prediction of difficult intubation. Int J Prev Med. 2013; 4(9): 1063-9[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments